Cary Street Partners Investment Advisory’s Organon & Co OGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-304
Closed -$4.53K 606
2025
Q1
$4.53K Buy
304
+148
+95% +$2.28K ﹤0.01% 515
2024
Q4
$2.33K Buy
+156
New +$2.54K ﹤0.01% 480
2024
Q1
Sell
-1,276
Closed -$18.4K 711
2023
Q4
$18.4K Sell
1,276
-57
-4% -$775 ﹤0.01% 645
2023
Q3
$23.1K Buy
1,333
+423
+46% +$8.82K ﹤0.01% 1072
2023
Q2
$18.9K Sell
910
-258
-22% -$5.61K ﹤0.01% 1060
2023
Q1
$27.5K Buy
1,168
+174
+18% +$4.67K ﹤0.01% 892
2022
Q4
$27.8K Buy
+994
New +$25.4K ﹤0.01% 885

Other funds holding OGN

Cary Street Partners Investment Advisory's OGN Position: Q2 2025 in Review

Cary Street Partners Investment Advisory sold out of Organon & Co (OGN) in Q2 2025, closing a stake of 304 shares — an estimated $4.53K sold.

Cary Street Partners Investment Advisory first reported a position in OGN in Q4 2022 and held it in 7 quarters. The position peaked at $27.8K in Q4 2022. 695 funds tracked by Wall St. Rank hold OGN as of Q2 2025.

  • Cary Street Partners Investment Advisory reported no remaining Organon & Co position as of Q2 2025 after selling out during the quarter.
  • Cary Street Partners Investment Advisory sold 304 Organon & Co shares in Q2 2025, an estimated $4.53K.
  • Cary Street Partners Investment Advisory first reported a position in Organon & Co in Q4 2022 and held it in 7 quarters.
  • Cary Street Partners Investment Advisory's Organon & Co position peaked at $27.8K in Q4 2022.
  • 695 funds tracked by Wall St. Rank held Organon & Co as of Q2 2025.

Based on Cary Street Partners Investment Advisory's 13F filing for Q2 2025, filed 13 Aug 2025.